Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [31] Ranibizumab Pre-Filled Syringe Versus Ranibizumab Vial: Syringe Preparation Time in Real-World Clinical Practice
    Souied, Eric
    Nghiem-Buffet, Sylvia
    Leteneux, Claudia
    Bayer, Sascha
    Derveloy, Audrey
    Sagkriotis, Alexandros
    Becker, Guido
    Cohen, Salomon-Yves
    OPHTHALMOLOGICA, 2014, 232 : 70 - 70
  • [32] Erratum: Ranibizumab for the treatment of wet AMD: a summary of real-world studies
    V Chong
    Eye, 2016, 30 : 1526 - 1526
  • [33] Real-World Canadian Study to Compare the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Ranibizumab and Aflibercept Vial
    Giunta, Michel
    Lalonde, Laurent
    Cordahi, Ghassan
    Saurel, Patrick
    Scarino, Andrea
    OPHTHALMOLOGICA, 2016, 236 : 7 - 7
  • [34] Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: The SUMMIT Study
    Sulahria, Humza
    Khan, Hannah
    Aziz, Aamir Abdul
    Khan, Huma
    Sheth, Veeral
    Graff, Jordan M.
    Eichenbaum, David Aaron
    Khanani, Arshad M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [35] LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLOARTHRITIS
    Pinto, A. S.
    Flora, K.
    Matharu, D.
    Isaacs, A.
    Machado, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 780 - 780
  • [36] Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial) : Real-World Evidence
    Chakraborty, Debdulal
    Mondal, Soumen
    Boral, Subhendu
    Das, Arnab
    Sinha, Tushar Kanti
    Majumdar, Saptorshi
    Bhattacharya, Ranabir
    Maitra, Ritobroto
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1067 - 1076
  • [37] Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar
    Kay, Jonathan
    Doerner, Thomas
    Emery, Paul
    Kvien, Tore K.
    Breedveld, Ferdinand C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (04) : E44 - +
  • [38] REAL-WORLD TREATMENT PATTERNS OF RANIBIZUMAB AMONG PATIENTS WITH RETINAL DISEASES IN CANADA: 5 YEARS OF DATA
    Rousseau, C.
    Saad, R.
    Davies, B.
    Zaour, N.
    VALUE IN HEALTH, 2015, 18 (07) : A428 - A428
  • [39] Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema
    Koc, Irem
    Kadayifcilar, Sibel
    Eldem, Bora
    OPHTHALMOLOGICA, 2018, 239 (2-3) : 85 - 93
  • [40] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
12345